ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Bristol-Myers Discontinues Development of Hepatitis C Drug

By Nathalie Tadena Bristol-Myers Squibb Co. (BMY) said Thursday it has discontinued the development of a drug intended to treat the liver disease hepatitis C in the interest of patient safety, after a patient died and others were hospitalized. Bristol-Myers earlier this month voluntarily suspended a Phase 2 study of BMS-986094, which was formerly known as INX-189, a nucleotide polymerase inhibitor, or "nuke." The initial case of heart failure, which was the basis for halting the study, subsequently resulted in death, the company said Thursday. Bristol-Myers said it is working with the U.S. Food and Drug Administration and clinical study investigators to conduct ongoing and close follow-ups of all the study's patients. To date, nine patients have been hospitalized, including the initial patient, and two remain hospitalized. The company said the cause of these unexpected events, which involve heart and kidney toxicity, hasn't been definitively established. Bristol-Myers decision to halt the study earlier this month raised questions about the experimental drug's potential and the $2.5 billion price tag Bristol paid earlier this year to buy the company that developed it. The suspension was considered a significant setback for the drug maker--already grappling with weak sales of its Plavix anticlotting drug that lost patent protection in May--in the race to develop new hepatitis C treatments. Bristol-Myers as well as other companies such as Gilead Sciences Inc. (GILD) and Abbott Laboratories (ABT) has been looking to bring the first all-oral hepatitis C regimen to market, hoping to tap what is expected to be a multibillion-dollar market for such a therapy. To strengthen its hepatitis C position, Bristol-Myers in February shelled out $2.5 billion to buy Inhibitex Inc. at a whopping 163% premium. Bristol was lured primarily by Inhibitex's nuke for hepatitis C, though it did acquire other potential treatments for infectious disease in the deal. Treatments for hepatitis C are considered lucrative because the disease is prevalent in large sections of the global population. The virus, which can be transmitted sexually or through use of shared needles and at tattoo parlors, affects some 170 million people world-wide. Separately, Synergy Pharmaceuticals Inc. (SGYP) said it has agreed to acquire the assets related to shingles treatment FV-100 from Bristol-Myers. FV-100 was developed by Inhibitex. Shares were up by 10 cents to $32.25 after hours. The stock has fallen 8.8% since the start of the year. -Write to Nathalie Tadena at nathalie.tadena@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Gilead Sciences (GILD)
DateTimeHeadline
04/27/201513:03:02Biotech Bubble Bursting? 3 Stocks I Want to Buy
04/27/201510:10:09Bristol-Myers Hepatitis C Therapy With Sovaldi Meets Study Goals
04/27/201509:46:17Bristol-Myers Hepatitis C Therapy With Sovaldi Meets Study Goals
04/27/201504:58:43Gilead Sciences Now Covered by Oppenheimer (GILD)
04/26/201513:02:02Can You Guess Which State Won't Pay for Hepatitis C Drugs?
04/26/201509:17:43MARKET SNAPSHOT: Apple, Energy, Health Care Earnings To Dominate...
04/26/201508:01:02Why Healthcare is the Best Sector For Your Money
04/26/201505:47:00Gilead gibt Ergebnisse aus Studien zu auf Sofosbuvir basierenden...
04/25/201522:14:00Gilead annonce les résultats d'études évaluant des traitements à...
04/25/201522:14:00Gilead comunica i risultati derivati dagli studi condotti ai...
04/25/201501:00:00Gilead Announces Results From Studies Evaluating Sofosbuvir-Based...
04/24/201515:46:50Gilead Sciences Stock Rating Reaffirmed by Morgan Stanley (GILD)
04/24/201510:48:12Correction to Merck Hepatitis C Treatment Story Update
04/24/201510:26:22Merck: Hepatitis C Treatment Shows 95% Cure Rate -- Update
04/24/201508:20:16Merck Says Experimental Hepatitis C Treatment Shows 95% Cure...
04/24/201507:57:21Merck Says Experimental Hepatitis C Treatment Shows 95% Cure...
04/24/201507:46:08EMA Recommends Avoidance of Some Hepatitis C Drugs With Amiodarone
04/24/201502:56:00Harvoni und Sovaldi von Gilead zeigen Wirksamkeit und Sicherheit...
04/23/201517:02:33Nasdaq Composite Closes at Record High
04/23/201517:00:00Gilead Sciences to Release First Quarter 2015 Financial Results...

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad